drugset / Trial / NCT03276052
A Phase I, Open-Label, Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Participants
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A Phase I, single centre, open-label study to investigate the pharmacokinetics (PK), safety and tolerability of single and multiple twice daily doses of inhaled Aclidinium Bromide in healthy Chinese male and female subjects.
Timeline
- Start
- 2021-10-14
- Primary completion
- 2021-11-26
- Completion
- 2021-11-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aclidinium | Small molecule | 400 ug | Inhaled |
Indications
No indication recorded.